XY Therapeutics ApS — Credit Rating and Financial Key Figures

XY Therapeutics ApS (CVR number: 41120681) is a company from GENTOFTE. The company recorded a gross profit of 2680.6 kDKK in 2023. The operating profit was -1031.8 kDKK, while net earnings were -1369.9 kDKK. The profitability of the company measured by Return on Assets (ROA) was -8.9 %, which can be considered poor and Return on Equity (ROE) was -28 %, which can be considered poor. The equity ratio, a key indicator for solidity, stood at -60.2 %. This indicates that the company's debt surpasses the value of its total assets, posing significant financial risk. XY Therapeutics ApS's liquidity measured by quick ratio was 1.3 which is at a high level. Thus, the company is in a strong financial position, with liquid assets surpassing current liabilities. It is well-prepared to cover short-term financial obligations.